Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Expenditures (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Capital Expenditures for 7 consecutive years, with $159000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 31.17% to $159000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $314000.0, a 12.95% increase, with the full-year FY2025 number at $314000.0, up 12.95% from a year prior.
  • Capital Expenditures was $159000.0 for Q4 2025 at Fulcrum Therapeutics, up from $90000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.3 million in Q2 2022 to a low of -$1.5 million in Q3 2022.
  • A 5-year average of $61210.5 and a median of $79000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 520.71% in 2022, then skyrocketed 1183.33% in 2023.
  • Fulcrum Therapeutics' Capital Expenditures stood at -$1.2 million in 2021, then soared by 100.52% to $6000.0 in 2022, then surged by 1183.33% to $77000.0 in 2023, then surged by 200.0% to $231000.0 in 2024, then tumbled by 31.17% to $159000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Capital Expenditures are $159000.0 (Q4 2025), $90000.0 (Q3 2025), and $65000.0 (Q2 2025).